** Shares of Lumos Diagnostics LDX.AX rise as much as 12.8% to A$0.265, highest level since May 12, 2022
** Q1 product revenue rises four-fold to $1.2 million, helped by increasing adoption of FebriDx across the U.S.
** FebriDx is co's rapid point of care test to help differentiate between bacterial and non-bacterial acute respiratory infections
** YTD, shares have risen more than seven-fold in value
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.